3 September, 2025
Turning Deviations and CAPA Into Opportunities for Improvement
In the life sciences sector, quality is not just a regulatory requirement, it is the foundation of trust. Every deviation, non-conformity, or ineffective CAPA plan has the potential to create ripple effects: reputational damage, recurring quality issues, operational inefficiencies, data integrity concerns, or even regulatory findings such as FDA 483s.
2 July, 2025
Our new solution for our Medical Devices clients: V&V Strategy Assessment
At GXP CONSULTING, we’re excited to introduce a new service tailored to one of the critical stages of medical device development: Verification & Validation (V&V).
19 June, 2025
Quick Impact Assessment – Project Plan Review for MedTech industries
We are pleased to announce the launch of a new high-value support format designed specifically for MedTech companies: the Quick Impact Assessment – Project Plan Review.
19 June, 2025
Participation in the A3P Switzerland Forum on Microbiology - June 17, 2025
On June 17, 2025, we were pleased to participate in the A3P Switzerland Forum on Microbiology, a key industry event focused on the latest advances in microbiological methods and technologies.
